98%
921
2 minutes
20
Background: Hyperkalemia is a potentially life-threatening condition, with guidelines recommending urgent treatment when the serum potassium level is greater than 6.0 mmol/L. However, these recommendations are inconsistent, leading to diverse approaches to patient care.
Objectives: The primary objectives were to use population-based datasets to determine how often outpatient hyperkalemia (K > 6.2 mmol/L) occurs and how frequently patients present to the emergency department (ED) within 24 hours of the hyperkalemia report. Secondary objectives were to compare the characteristics of patients who had an ED encounter to those who did not, assess clinical outcomes within 7 days of the hyperkalemia report, and describe the initial potassium result within 24 hours of an ED encounter.
Design: Retrospective cohort study using linked population-based datasets at ICES.
Setting: Ontario, Canada from January 1, 2007, to December 24, 2021.
Patients: Adult patients (≥18 years) not on dialysis with an outpatient hyperkalemia result >6.2 mmol/L who were identified through flagged and urgently communicated results from outpatient laboratories.
Measurements: Emergency department encounters within 24 hours following an outpatient serum potassium report >6.2 mmol/L. Outcomes included all-cause mortality, cardiovascular mortality, arrhythmias, cardiac arrest in the ED, hospitalizations, and new dialysis starts within 7 days of the hyperkalemia report.
Methods: Administrative healthcare data were linked with laboratory results to compare baseline characteristics, medication use, healthcare utilization, and clinical outcomes for all patients. Standardized differences were used for comparisons.
Results: There were over 65 million serum potassium measurements and 57 607 individuals with an outpatient hyperkalemia value >6.2 mmol/L. Of these, 7469 (13.0%) individuals had an ED encounter within 24 hours. Individuals with an ED encounter had more comorbidities, higher medication use, and more prior healthcare utilization. Within 7 days of the hyperkalemia report, 675 of the 57 607 individuals (1.2%) had died. Where data were available, the first potassium value within 24 hours of an ED encounter was 1.5 mmol/L (± SD 1.3) lower, on average, than the initial outpatient potassium value.
Limitations: All-cause mortality may not be attributable to the hyperkalemia result. Sudden cardiac death, which is more specific to hyperkalemia, is not completely captured in our data sources. Data for medications are limited to patients 65 years of age and older.
Conclusions: Outpatient hyperkalemia is common. Despite guidelines recommending urgent treatment for patients with serum potassium levels >6.2 mmol/L, most are not referred to the ED.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317165 | PMC |
http://dx.doi.org/10.1177/20543581251356568 | DOI Listing |
Br J Clin Pharmacol
August 2025
Internal Medicine IX: Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty/Heidelberg University Hospital, Heidelberg, Germany.
Aim: To develop a dynamic prediction model for potassium concentration in the outpatient sector for patients with heart failure (HF), chronic kidney disease (CKD) and/or diabetes mellitus (DM).
Methods: We used administrative claims data from Scotland collected at the Tayside Health Informatics Centre and selected patients between 1 January and 30 June 2020 with underlying conditions of HF, CKD and/or DM. The follow-up time of each patient was divided into assessment periods to predict a patient's maximum potassium value within the next 4 weeks (prediction periods).
Eur J Heart Fail
August 2025
Saint Luke's Mid America Heart Institute and University of Missouri, Kansas City, MO, USA.
Aims: Patients with heart failure (HF) at high risk for hyperkalaemia are underrepresented in prospective HF registries. The CARE-HK in HF registry sought to characterize prospectively the clinical profile, management, and outcomes for patients with HF at high risk of hyperkalaemia.
Methods And Results: CARE-HK in HF was a multinational prospective registry of outpatients with HF (regardless of left ventricular ejection fraction [LVEF]) treated with an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor (ACEI/ARB/ARNI) and either receiving or potential candidate for a mineralocorticoid receptor antagonist (MRA).
Cureus
August 2025
Acute Medicine, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, GBR.
Very-late-onset multiple sclerosis (VLOMS), defined as disease onset after the age of 60, is a rare and often diagnostically challenging entity that may present with atypical features. We describe the case of a 67-year-old man who presented with progressive urinary symptoms culminating in obstructive uropathy and acute kidney injury (AKI), ultimately diagnosed as progressive multiple sclerosis (MS). The patient had a three-year history of left upper limb weakness and gait difficulty, which had been previously unexplored.
View Article and Find Full Text PDFCan J Kidney Health Dis
July 2025
Division of Nephrology, Department of Medicine, Western University, and London Health Sciences Centre, ON, Canada.
Background: Hyperkalemia is a potentially life-threatening condition, with guidelines recommending urgent treatment when the serum potassium level is greater than 6.0 mmol/L. However, these recommendations are inconsistent, leading to diverse approaches to patient care.
View Article and Find Full Text PDFAACE Endocrinol Diabetes
April 2025
Department of Internal Medicine, St. Joseph's University Medical Center, Paterson, New Jersey.
Background/objective: Thyrotoxic periodic paralysis is a rare, life-threatening complication of thyrotoxicosis, characterized by hypokalemia, hyperthyroidism, and acute muscle weakness. It often occurs in Graves' disease but is not directly linked to the severity or duration of thyrotoxicosis. The objective of this report is to describe a patient with Graves' disease and thyrotoxic periodic paralysis, emphasizing the importance of achieving an euthyroid state, potassium repletion, and the role of β-blockers in management.
View Article and Find Full Text PDF